170 related articles for article (PubMed ID: 22530992)
21. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
22. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Wang L; Pearson K; Ferguson JE; Clark RE
Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
[TBL] [Abstract][Full Text] [Related]
23. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
24. [Chronic myeloid leukemia and imatinib: Experience at the Lome Campus teaching hospital (Togo)].
Segbena AY; Kueviakoe IM; Agbetiafa K; Padaro E; Layibo Y; Dorkenoo A; Agbo YM; Bories D
Med Sante Trop; 2012; 22(3):307-11. PubMed ID: 23174189
[TBL] [Abstract][Full Text] [Related]
25. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Smith BD; Kasamon YL; Kowalski J; Gocke C; Murphy K; Miller CB; Garrett-Mayer E; Tsai HL; Qin L; Chia C; Biedrzycki B; Harding TC; Tu GH; Jones R; Hege K; Levitsky HI
Clin Cancer Res; 2010 Jan; 16(1):338-47. PubMed ID: 20048335
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
28. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Yeung DT; Dang P; Goyne JM; Slader C; Filshie RJ; Mills AK; Melo JV; White DL; Grigg AP; Hughes TP
Blood; 2013 Jul; 122(4):515-22. PubMed ID: 23704092
[TBL] [Abstract][Full Text] [Related]
30. [Tolerability of imatinib for patients with chronic myelogeneous leukemia (CML)].
Imataki O; Shintani T; Waki F; Ohnishi H; Ishida T
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1863-7. PubMed ID: 19011333
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Borthakur G; Cortes JE
Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
[TBL] [Abstract][Full Text] [Related]
32. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
Allen-Bard S
Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
34. Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
Sánchez-Guijo F
Leuk Res; 2014 Oct; 38(10):1156-7. PubMed ID: 25113280
[No Abstract] [Full Text] [Related]
35. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Rousselot P; Huguet F; Rea D; Legros L; Cayuela JM; Maarek O; Blanchet O; Marit G; Gluckman E; Reiffers J; Gardembas M; Mahon FX
Blood; 2007 Jan; 109(1):58-60. PubMed ID: 16973963
[TBL] [Abstract][Full Text] [Related]
36. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Burchert A; Saussele S; Eigendorff E; Müller MC; Sohlbach K; Inselmann S; Schütz C; Metzelder SK; Ziermann J; Kostrewa P; Hoffmann J; Hehlmann R; Neubauer A; Hochhaus A
Leukemia; 2015 Jun; 29(6):1331-5. PubMed ID: 25712735
[TBL] [Abstract][Full Text] [Related]
37. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
38. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
39. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
40. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
